Clinical trial · Interventional
Analytical Validation of Circulating DNA Analysis Methods: Creation of a Control Cohort
NCT07663994CI-TRIAL-00124113HD-DNAcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Pilot, prospective, mono-center study conducted in a population of healthy participants (free of cancer) for the analytical validation of circulating DNA analysis methods. The participants are employees of the institution. Their recruitement is carried out via internal posting (intranet and bulletin boards). The study participation will be strictly voluntary and without consequences on the professional situation of the participants.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Healthy Volunteers (Cancer) | Malignant Neoplasm | ALIAS | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 1 single blood draw after in the inclusion of the participant in the study (Up to 30 mL). | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Blood draw for analysis
- interventionNames
- Diagnostic Test: 1 single blood draw after in the inclusion of the participant in the study (Up to 30 mL).
Primary outcomes (1)
- measure
- Proportion of participants for which no pathogenic mutation has been detected on the MSK-Access panel.
- timeFrame
- baseline
- description
- Ratio of number of participants without pathogenic mutation on the MSK-Access panel over the total number of participants
Secondary outcomes (4)
- measure
- Proportion of participants for wich no pathogenic mutation has been detected on the HRR-Liq panel
- timeFrame
- baseline
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 1 Adult volunteer (≥ 18 y.o.) * 2 Participant free of cancer * 3 Participant belonging to the personnel of Oncopole Claudius Regaud (IUCT-O) institution * 4 Participant affiliated to a Social Health Insurance in France * 5 Participant who received clear and understandable information about the research * 6 Participant who signed an informed consent form before inclusion into the study and before any study specific procedure * 7 Participant who accepts a blood draw in the context of the research * 8 Participant who agrees to be contacted in the event of an incidental finding of a potential genetic abnormality Exclusion Criteria: * 1 Participant presenting with an associated pathology potentially preventing the adequate conduct of the study procedure * 2 Participant presenting with a contra-indication to blood draw * 3 Participant who reports to the investigator team * 4 Participant who has forfeited his/her freedom bu administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice)
References
Publications (0)
Data not yet available
No reference posted for this study.